EUCTR2004-005262-20-BE
Active, not recruiting
Phase 1
A phase IV, single-blinded, randomized, single centre study to demonstrate the non-inferiority of immunogenicity elicited by GSK Biologicals’ hepatitis B vaccine, Engerix-B in multidose presentation to that elicited by Engerix-B in monodose presentation when administered according to 0, 1, 6 months schedule in healthy adults aged equal to or above 18 years. - HBV-308
DrugsEngerix-B
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- GlaxoSmithKline Biologicals
- Enrollment
- 280
- Status
- Active, not recruiting
- Last Updated
- 9 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Male or female adult aged greater than or equal to 18 years, who is free from obvious health problems and from whom written informed consent is obtained. If the subject is a female then she must be of non\-childbearing potential, i.e. either surgically sterilized or one year post\-menopausal; or, if of childbearing potential, she must be abstinent or have used adequate contraceptive precautions for 30 days prior to vaccination, have a negative pregnancy test and must agree to continue such precautions for two months after completion of the vaccination series.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1\.2 Adults (18\-64 years) yes
- •F.1\.2\.1 Number of subjects for this age range
- •F.1\.3 Elderly (\>\=65 years) yes
- •F.1\.3\.1 Number of subjects for this age range
Exclusion Criteria
- •Use of any investigational or non\-registered drug or vaccine other than the study vaccine during the study period.
- •Chronic administration (defined as more than 14 days) of immunosuppressants or other immune\-modifying drugs within six months prior to the first vaccine dose. (For corticosteroids, this will mean prednisone, or equivalent, ? 0\.5 mg/kg/day. Inhaled and topical steroids are allowed.)
- •Planned administration/ administration of a vaccine not foreseen by the study protocol within 30 days of the first dose of vaccine.
- •Previous vaccination against hepatitis B
- •History of hepatitis B infection
- •Acute disease at the time of enrolment.
- •Acute or chronic, clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by physical examination or laboratory screening tests.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
Evaluation of the effectiveness of the antibiotic therapy in preventing complications after tooth extraction and evaluation of the effectiveness of the probiotic in preventing antibiotic adverse effectteeth needing extraction due to infectionsMedDRA version: 21.1Level: PTClassification code 10062132Term: Tooth extractionSystem Organ Class: 10042613 - Surgical and medical proceduresMedDRA version: 20.0Level: PTClassification code 10044034Term: Tooth disorderSystem Organ Class: 10017947 - Gastrointestinal disordersTherapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Surgical Procedures, Operative [E04]EUCTR2016-001916-39-ITAZIENDA OSPEDALIERO-UNIVERSITARIA PISANA150
Active, not recruiting
Phase 1
A study to evaluate immunogenicity and safety of GlaxoSmithKline (GSK)'s Infanrix hexa vaccine (DTPa HBV IPV/Hib) versus MCM Vaccine BV's Vaxelis vaccine (DTaP5 HBV IPV Hib) in healthy infants and toddlersEUCTR2019-002988-10-ITGLAXOSMITHKLINE BIOLOGICALS500
Active, not recruiting
Phase 1
A study to evaluate immunogenicity and safety of GlaxoSmithKline (GSK)’s Infanrix hexa vaccine (DTPa HBV IPV/Hib) versus MCM Vaccine BV’s Vaxelis vaccine (DTaP5 HBV IPV Hib) in healthy infants and toddlersHealthy volunteers [Primary and booster immunization of infants and toddlers against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and disease caused by Haemophilus influenzae type b (Hib)]MedDRA version: 21.1Level: LLTClassification code 10054187Term: Polio immunizationSystem Organ Class: 10042613 - Surgical and medical proceduresMedDRA version: 21.1Level: PTClassification code 10069533Term: Haemophilus influenzae type b immunisationSystem Organ Class: 10042613 - Surgical and medical proceduresMedDRA version: 21.1Level: LLTClassification code 10069593Term: Pertussis immunizationSystem Organ Class: 10042613 - Surgical and medical proceduresMedDRA version: 21.1Level: LLTClassification code 10054181Term: Hepatitis B immunizationSystem Organ Class: 10042613 - Surgical and medical proceduresMedDRA version: 21.1Level: LLTClassification code 10054180Term: Diphtheria immunizationSystem Organ Class: 10042613 - Surgical and medical proceduresMedDRA version: 21.1Level: LLTClassification code 10054183Term: Tetanus immunizationSystem Organ Class: 10042613 - Surgical and medical proceduresTherapeutic area: Diseases [C] - Bacterial Infections and Mycoses [C01]EUCTR2019-002988-10-DEGlaxoSmithKline Biologicals SA500
Not yet recruiting
Phase 4
A clinical study to evaluate the efficacy and safety of Nisha-Amalki capsules in preventing progression to Diabetes in patients with Pre-DiabetesCTRI/2018/08/015503PHARMANZA HERBAL PVT LTD
Active, not recruiting
Not Applicable
Immunogenicity and safety of BoostrixTM using a new syringe in 10 to 15-year-old adolescents.EUCTR2013-003768-30-Outside-EU/EEAGlaxoSmithKline Biologicals671